Key Financial Figures - Standalone (Rs. in Lakhs)

Quarterly Performance (Q2 FY2026)

  • Total Revenue: ₹4,087.75
  • From operations: ₹4,072.37
  • Other income: ₹15.38
  • Total Expenses: ₹3,578.84
  • Cost of materials consumed: ₹3,822.03
  • Change in inventories: (₹452.17) [negative indicates decrease]
  • Employee benefits: ₹42.74
  • Finance cost: ₹39.11
  • Depreciation: ₹18.46
  • Other expenses: ₹108.67
  • Profit before tax: ₹508.91
  • Tax expense: ₹129.79
  • Current tax: ₹145.58
  • Deferred tax: (₹15.79) [tax benefit]
  • Net profit for period: ₹379.12
  • Earnings per share (Rs. 10 face value):
  • Basic: ₹0.866
  • Diluted: ₹0.862

Half-Yearly Performance (H1 FY2026)

  • Total Revenue: ₹8,042.37
  • Profit before tax: ₹1,004.56
  • Net profit: ₹749.80
  • Earnings per share:
  • Basic: ₹1.726
  • Diluted: ₹1.719

Key Financial Figures - Consolidated (Rs. in Lakhs)

Quarterly Performance (Q2 FY2026)

  • Total Revenue: ₹10,820.11
  • From operations: ₹10,794.28
  • Other income: ₹25.83
  • Profit before tax: ₹1,533.15
  • Net profit for period: ₹977.04
  • Earnings per share (Rs. 10 face value):
  • Basic: ₹2.231
  • Diluted: ₹2.221

Half-Yearly Performance (H1 FY2026)

  • Total Revenue: ₹20,927.49
  • Profit before tax: ₹2,568.16
  • Net profit: ₹1,919.21
  • Earnings per share:
  • Basic: ₹4.419
  • Diluted: ₹4.400

Balance Sheet Highlights (Standalone as of 30th September 2026)

  • Total Assets: ₹41,681.70 lakhs
  • Non-current assets: ₹29,295.06 lakhs
  • Property, plant and equipment: ₹1,123.22 lakhs
  • Investment in Sriven Pharmachem India Pvt Ltd: ₹27,716.95 lakhs
  • Current assets: ₹12,386.63 lakhs
  • Inventories: ₹4,721.37 lakhs
  • Trade receivables: ₹7,278.43 lakhs
  • Total Equity: ₹33,911.12 lakhs
  • Share capital: ₹4,381.45 lakhs
  • Other equity: ₹29,529.67 lakhs
  • Current liabilities: ₹7,486.42 lakhs
  • Borrowings: ₹1,375.06 lakhs
  • Trade payables: ₹5,393.41 lakhs

Cash Flow Statement (Standalone H1 FY2026)

  • Net cash used in operating activities: (₹829.58) lakhs
  • Net cash used in investing activities: (₹11.77) lakhs
  • Net cash from financing activities: ₹578.52 lakhs
  • Net decrease in cash: (₹262.83) lakhs

Important Notes and Disclosures

1. The financial results were reviewed by the Audit Committee and approved by the Board of Directors on 13th November, 2026.

2. The company operates in a single business segment: 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs)'.

3. The company has one material wholly-owned subsidiary: Sriven Pharmachem India Private Limited.

4. The company changed its name due to change in business activity and is required to include turnover from new activities separately for 3 years, but since it carries only one activity, separate disclosure is not provided.

5. The standalone results are available on the company's website: https://astallabs.com/

6. The auditors, Sathuluri & Co., issued an unqualified limited review report for both standalone and consolidated results.